Hong Kong Commercial Services Stock News

Earlier this week, China Resources Land announced it would sell approximately 49.5 million shares of China Resources Mixc Lifestyle Services for about HK$2 billion, reducing its stake from 72.29% to 70.12%. This transaction was executed at nearly a 10 percent discount to the previous closing price and is intended to raise funds for acquiring land reserves and covering development costs. We'll consider how this reduced ownership stake and discounted placement could influence the company's...

Yue Yuen Industrial (Holdings) reported earnings for the nine months ended September 30, 2025, with sales of US$6.02 billion and net income of US$278.72 million, both reflecting decreases compared to the same period last year. The declines in both sales and profitability suggest that operational challenges or shifting market demand may have impacted the company's core business during this period. We’ll explore how the dip in net income shapes Yue Yuen Industrial’s investment narrative and...

Prada (SEHK:1913) has seen its shares fluctuate this week, prompting investors to take a closer look at what is driving recent price action. The past month has delivered modest gains, raising some interesting valuation questions. See our latest analysis for Prada. Prada’s latest week of trading brought a mix of volatility and modest upward movement, with a 5.8% 7-day share price return standing out within an ongoing period of market recalibration. While momentum has been choppy lately, it’s...

Earlier in November 2025, CARsgen Therapeutics Holdings announced updated clinical data for its allogeneic CAR-T cell therapy candidates, CT0596 and CT1190B, revealing initially favorable safety and efficacy outcomes in heavily pretreated patients with relapsed/refractory multiple myeloma and non-Hodgkin’s lymphoma. An interesting insight is that some patients who had failed multiple previous advanced therapies achieved complete responses, highlighting the potential impact of these...

Semiconductor Manufacturing International Corporation ( HKG:981 ) shareholders are probably feeling a little...

Investors in InnoCare Pharma Limited ( HKG:9969 ) had a good week, as its shares rose 8.4% to close at HK$15.17...

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...

Nine Dragons Paper (Holdings) Limited ( HKG:2689 ), is not the largest company out there, but it led the SEHK gainers...

It looks like Laopu Gold Co., Ltd. ( HKG:6181 ) is about to go ex-dividend in the next 3 days. The ex-dividend date is...

When close to half the companies in Hong Kong have price-to-earnings ratios (or "P/E's") above 13x, you may consider...

If you're looking for a multi-bagger, there's a few things to keep an eye out for. Firstly, we'd want to identify a...

Key Insights Using the 2 Stage Free Cash Flow to Equity, KLN Logistics Group fair value estimate is HK$13.52 KLN...

Looking at Wynn Macau, Limited's ( HKG:1128 ) insider transactions over the last year, we can see that insiders were...

Despite an already strong run, Lapco Holdings Limited ( HKG:8472 ) shares have been powering on, with a gain of 28% in...

TI Cloud Inc. ( HKG:2167 ) insiders who acquired shares over the previous 12 months, can probably afford to ignore the...

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...

The Qing Hua Holding Group Company Limited ( HKG:8082 ) share price has done very well over the last month, posting an...

Many SITC International Holdings Company Limited ( HKG:1308 ) insiders ditched their stock over the past year, which...

JD Health International reported stronger-than-expected third quarter results, partnered with leading pharmaceutical companies, and announced agreements with JD.com involving technology support, supply chain solutions, and healthcare services, with these deals to be voted on at an upcoming general meeting. JD Health’s advances in digital healthcare and ongoing collaborations have reinforced its leadership in online specialty medicines and expanded the reach of its smart health ecosystem...

Meituan (SEHK:3690) has recently seen its stock fluctuate, drawing attention from investors who are watching the company’s performance over the past month. There is growing curiosity about what is driving sentiment around the stock now. See our latest analysis for Meituan. Zooming out, Meituan’s share price has struggled to regain its footing this year. Momentum has faded since January and a 1-year total shareholder return of -41.04% highlights the challenging climate for the stock. Recent...

HBM Holdings (SEHK:2142) has announced a strategic partnership with Evinova China to leverage artificial intelligence and digital technologies in biologics research and development. This move is expected to add momentum to its innovation pipeline and market positioning. See our latest analysis for HBM Holdings. HBM Holdings’ latest surge, up 4% in a single day and 11.6% over the last week, follows the announcement of its AI-driven partnership with Evinova China. This signals that investors...

Lianlian DigiTech (SEHK:2598) has been catching some attention lately, with shares moving in various directions over the past week and month. Investors are weighing recent trading patterns in relation to the company’s overall financial trajectory. See our latest analysis for Lianlian DigiTech. Lianlian DigiTech’s share price has swung lower over the past quarter, with a 90-day share price return of -17.96% and a one-year total shareholder return of -13.4%. While momentum has faded recently,...

Earlier this week, Genscript Biotech Corporation announced that its associate, Legend Biotech Corporation, reported a significant reduction in net losses for the third quarter of 2025, alongside strong sales growth for its CARVYKTI product. This disclosure, released around Genscript’s Analyst/Investor Day, places enhanced focus on the financial ties between the two companies and the implications for Genscript’s broader business outlook. We’ll now explore how Legend Biotech’s improved...

Precision Tsugami (China) Corporation Limited recently announced its half-year earnings, reporting sales of CNY 2,496.9 million and net income of CNY 502.25 million for the period ended September 30, 2025, both of which were higher than the prior year. The company's substantial increases in both revenue and earnings per share highlight ongoing momentum in its operational performance and profitability. We'll explore how this robust earnings growth shapes Precision Tsugami (China)'s investment...